Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.97 |
| ▸ | RAB9A | P51151 | 4/20 | 0.97 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.81 |
| ▸ | HPGD | P15428 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | CTSD | P07339 | 1/20 | 0.81 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.81 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.81 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.81 |
| ▸ | MAOA | P21397 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115705 | 1.00 | MAOB (1.00) | MAOBNPC1RAB9ATRPV1KDM4E | |
| Ilepcimide SCHEMBL3838030 | 0.99 | NPC1 (1.00) | MAOBNPC1RAB9ATRPV1KDM4E | |
| Ilepcimide SCHEMBL30237912 | 0.99 | NPC1 (1.00) | MAOBNPC1RAB9ATRPV1KDM4E | |
| Ilepcimide SCHEMBL29738474 | 0.99 | NPC1 (1.00) | MAOBNPC1RAB9ATRPV1KDM4E | |
| Ilepcimide SCHEMBL668328 | 0.99 | NPC1 (1.00) | MAOBNPC1RAB9ATRPV1KDM4E | |
| Ilepcimide SCHEMBL30887538 | 0.99 | NPC1 (1.00) | MAOBNPC1RAB9ATRPV1KDM4E | |
| SCHEMBL10793053 | 0.95 | MAOB (0.90) | MAOBNPC1RAB9ATRPV1KDM4E | |
| SCHEMBL10793048 | 0.95 | MAOB (0.90) | MAOBNPC1RAB9ATRPV1KDM4E | |
| SCHEMBL22463688 | 0.91 | MAOB (0.84) | MAOBNPC1RAB9ATRPV1KDM4E | |
| Trichostachine SCHEMBL16274586 | 0.91 | MAOB (0.97) | MAOBNPC1RAB9ATRPV1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | claimed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | claimed |
| EP-2011495-A1 | Use of piperine and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | claimed |
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | disclosed |
| EP-2011495-A1 | Use of piperine and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-7122561-B2 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-20040061142-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2004-04-01 | — | — | US | disclosed |
| US-6680391-B2 | PIPERINE AND ANALOGUES OR DERIVATIVES FOR THE TREATMENT OF SKIN CONDITIONS TREATABLE BY STIMULATING MALENOCYTE PROLIFERATION, SUCH AS VITILGO, AND ALSO FOR SKIN CANCER | BTG INTERNATIONAL LIMITED (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20020168369-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2002-11-14 | — | — | US | disclosed |
| US-6346539-B1 | ADMINISTERING PIPERINE DERIVATIVE TO TREAT VITILIGO AND MELANOMA; STIMULATING MELANOCYTE PROLIFERATION; ANTICARCINOGENIC AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2002-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | PRPH, BDNF, GAP43 | MAOB 2252/4885NPC1 725/4885RAB9A 803/4885 |
| US-20020168369-A1 | Treatment of skin conditions | TYR, MC1R, MITF | MAOB 752/4885NPC1 4758/4885RAB9A 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.